• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex.
Conclusion and Relevance: Female patients with a high stroke risk were less likely to receive guideline-recommended treatment. This study provides new information on prescribing trends within the Australian setting and highlights the opportunity to improve the management of female patients with AF and 1 or more additional stroke risk factors. PMID: 32019321 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 3, 2020 Category: Drugs & Pharmacology Authors: Pilcher SM, Alamneh EA, Chalmers L, Bereznicki LR Tags: Ann Pharmacother Source Type: research

A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation
Conclusion Many residents with non-valvular AF and significant risk of stroke were not receiving oral anticoagulation despite a lack of documented reason for non-prescribing. Non-vitamin K antagonists were widely prescribed but dosing of these agents could still be improved. There remains a need to improve anticoagulant prescribing for aged care residents and optimise stroke prevention in this population.
Source: International Journal of Clinical Pharmacy - April 13, 2020 Category: Drugs & Pharmacology Source Type: research

Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation
Conclusions: Over the 10 years, OAC prescribing in high stroke risk patients with AF increased by one-third. There was considerable variation in OAC prescribing between general practices.
Source: Frontiers in Pharmacology - March 23, 2021 Category: Drugs & Pharmacology Source Type: research

The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation
ConclusionsThe apixaban and dabigatran trials may be the most representative of hospitalized patients with AF. The DOAC trial results can readily be extrapolated to, and guide prescribing for, at least two thirds of patients discharged from a large metropolitan health service in Australia.
Source: European Journal of Clinical Pharmacology - July 27, 2017 Category: Drugs & Pharmacology Source Type: research

Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study
ConclusionThe overall rate of bleeding in this cohort was low relative to similar observational studies. The rate of major bleeding was higher in patients prescribed warfarin compared to DOACs, with a similar rate of major bleeding for DOACs and antiplatelet agents. Our findings suggest potential to strategies to reduce bleeding include using DOACs in preference to warfarin, and avoiding multiple antithrombotic therapies in patients with AF.
Source: European Journal of Clinical Pharmacology - September 22, 2017 Category: Drugs & Pharmacology Source Type: research